75291-84-8

Usage

Uses

Used in Pharmaceutical Production:
5,6-Dichloronicotinamide is used as an intermediate in the production of pharmaceuticals due to its potential antimicrobial and antitumor properties. Its chemical structure allows it to be a building block for the synthesis of various biologically active compounds, contributing to the development of new medications.
Used in Dye Industry:
In the dye industry, 5,6-Dichloronicotinamide is utilized as a chemical intermediate for the synthesis of dyes. Its unique properties enable the creation of dyes with specific characteristics, such as color intensity and stability.
Used in Pesticide Formulation:
5,6-Dichloronicotinamide is also used in the formulation of pesticides. Its antimicrobial properties make it a valuable component in developing effective pest control solutions, contributing to agricultural productivity and crop protection.
Used in Research and Development:
In the field of research and development, 5,6-Dichloronicotinamide serves as a subject of study for its potential applications in medicine and other industries. Scientists investigate its properties and interactions to discover new uses and improve existing ones, pushing the boundaries of what is possible with 5,6-DICHLORONICOTINAMIDE.
It is crucial to follow proper handling and disposal procedures when working with 5,6-Dichloronicotinamide to minimize its environmental impact and ensure the safety of those who come into contact with it.

InChI:InChI=1/C6H4Cl2N2O/c7-4-1-3(6(9)11)2-10-5(4)8/h1-2H,(H2,9,11)

Upstream product

• 54127-29-6 5,6-dichloronicotinoyl chloride 
• 41667-95-2 5,6-dichloronicotinic acid 

Downstream Products

• 65189-15-3 5,6-dichloro-3-pyridinecarbonitrile 

Relevant academic research and scientific papers

METAL COMPLEXES, COMPRISING CARBENE LIGANDS HAVING AN O-SUBSTITUTED NON-CYCLOMETALATED ARYL GROUP AND THEIR USE IN ORGANIC LIGHT EMITTING DIODES

Cyclometallated Ir complex comprising three N,N diaryl substituted carbene ligands, bearing substituents in the 2 position of the non-cyclometallated aryl ring;an organic electronic device, preferably an organic light-emitting diode (OLED), comprising at least one cyclometallated Ir complexas described above, a light-emitting layer comprising said cyclometallated Ir complex preferably as emitter material, preferably in combination with at least one host material, use of said cyclometallated Ir complex in an OLED and an apparatus selected from the group consisting of stationary visual display units, mobile visualdisplay units, illumination units, units in items of clothing, units in handbags, units in accessoires, units in furniture and units in wallpaper comprising said organic electronic device, preferably said OLED, or said light-emitting layer. The present invention further relates to a process for the preparation of said cyclometallated Ir complex.

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H- benzimidazoles

The vanilloid receptor-1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2- ylpiperazin-1-yl)-1H-benzo-[d]imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant (CFA).

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.